other drugs, we'd say, well, the system worked. So that's an open question. I'll leave that to perhaps somebody more knowledgeable on thyroid therapy than I.
Plus, the Carr study, there are always questions about compliance. They did tablet counts, but whether that worked or not, there was no -- since that was an '88 study, we don't really know. They obviously went from one strength to the other in order to get the different strengths. There's no information available on content uniformity or potency as they moved to the different strengths.
I guess one substantive comment might be out of the Abbott study, the comment on a carryover, and I didn't hear much discussion of that. I know in the old days, FDA would fail a study if it had a carryover, and then they kind of backed off of that and said, well, if you can justify it or there's no reason for the carryover, it'll be okay. Is that still an issue, and should we be concerned about apparent carryover in the levothyroxine?
DR. KIBBE: That's a lot of questions. Is anybody jumping in here with answers? Go ahead.
DR. LESKO: Thank you, Art.